Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BiKePian in acute gouty arthritis (TCM damp-heat accumulation pattern)
CTR20251071Phase 3Active
- Sponsor
- Hefei Jinyue Pharmaceutical
- Start
- May 2025
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in acute gout flare comparing BiKePian with BiKePian placebo (2 arms). Primary endpoint: Change in joint pain VAS score from baseline at day 3. Started May 2025; status: active.
02
Drugs
colchicine
03
Conditions
acute gout flare
Beyond the preview
Go deeper on CTR20251071.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20251071.